Avadel Pharmaceuticals plc (AVDL) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 14 analysts1.0% Above Target
AVDL trades 1.0% above Wall Street's consensus target of $21.43.
Current Price$21.64
Average Target$21.43
Target
Current
Low$18.50
Median$20.00
High$30.00
Analyst Target Range
Forward P/E28.3x
(Growth Premium)
PEG Ratio—
Implied Growth—
Analyst Spread53.7%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes AVDL achieves its forward estimates and maintains a stable P/E multiple of 28.3x. This scenario reflects the blended consensus of 14 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
AVDL Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Avadel Pharmaceuticals plc (AVDL) has a Wall Street consensus price target of $21.43, based on estimates from 14 covering analysts. With the stock currently trading at $21.64, this represents a potential downside of -1.0%. The company has a market capitalization of $2.10B.
Analyst price targets range from a low of $18.50 to a high of $30.00, representing a 54% spread in expectations. The median target of $20.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, AVDL trades at a trailing P/E of -42.4x and forward P/E of 28.3x.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $3.07, with bear and bull scenarios of $1.93 and $4.04 respectively. Model confidence stands at 46/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+51.1%
Industry Consensus
Avg Forward P/E
22.2x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 JAZZJazz Pharmaceuticals plc | $14.1B | $224.66 | $257.44 | +14.6% | Buy | 8.9x | 48 |
 AXSMAxsome Therapeutics, Inc. | $12.9B | $250.50 | $262.38 | +4.7% | Buy | — | 26 |
 INVAInnoviva, Inc. | $1.7B | $22.49 | $37.00 | +64.5% | Buy | 6.3x | 10 |
 SUPNSupernus Pharmaceuticals, Inc. | $2.6B | $44.38 | $60.00 | +35.2% | Buy | 17.8x | 14 |
 PGNYProgyny, Inc. | $2.0B | $26.08 | $30.33 | +16.3% | Buy | 20.4x | 20 |
 NKTRNektar Therapeutics | $1.2B | $60.98 | $149.60 | +145.3% | Buy | — | 33 |
 COLLCollegium Pharmaceutical, Inc. | $1.1B | $33.54 | $58.00 | +72.9% | Buy | 4.3x | 12 |
 HALOHalozyme Therapeutics, Inc. | $8.1B | $68.55 | $88.25 | +28.7% | Buy | 8.5x | 27 |
 PRAXPraxis Precision Medicines, Inc. | $8.2B | $282.31 | $584.00 | +106.9% | Buy | — | 16 |
 PTCTPTC Therapeutics, Inc. | $6.6B | $78.98 | $95.83 | +21.3% | Buy | 89.1x | 26 |
AVDL — Frequently Asked Questions
Quick answers to the most common questions about buying AVDL stock.
What is the AVDL stock price target for 2026?
Wall Street's consensus price target for AVDL is $21.43, -1.0% from its current price of $21.64. The below-market target from 14 analysts suggests limited near-term appreciation.
Is AVDL a buy, sell, or hold?
AVDL has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $21.43 implies -1.0% downside from current levels.
Is AVDL stock overvalued or undervalued?
AVDL trades at a forward P/E of 28.2839x, representing a moderate valuation. With analysts targeting $21.43 (-1.0% implied move), the stock appears close to fair value.
How high can AVDL stock go?
The most bullish Wall Street analyst has a price target of $30 for AVDL, while the most conservative target is $18.5. The consensus of $21.43 represents the median expectation. Our quantitative valuation model projects a bull case target of $4 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover AVDL stock?
AVDL is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the AVDL stock forecast?
The 12-month AVDL stock forecast based on 14 Wall Street analysts shows a consensus price target of $21.43, with estimates ranging from $18.5 (bear case) to $30 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $3, with bear/bull scenarios of $2/$4.
What is AVDL's fair value based on fundamentals?
Our quantitative valuation model calculates AVDL's fair value at $3 (base case), with a bear case of $2 and bull case of $4. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 46/100.
What is AVDL's forward P/E ratio?
AVDL trades at a forward P/E ratio of 28.3x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy AVDL stock?
Analysts are cautious on AVDL, with 0 Sell ratings and a price target of $21.43 (-1.0% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do AVDL price targets vary so much?
AVDL analyst price targets range from $18.5 to $30, a 54% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21.43 consensus represents the middle ground. Our model's $2-$4 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare